Publicacións nas que colabora con Sergio Raposeiras Roubín (14)

2022

  1. Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries

    Frontiers in Cardiovascular Medicine, Vol. 9

2018

  1. Effect of beta-blocker dose on mortality after acute coronary syndrome

    Revista Portuguesa de Cardiologia, Vol. 37, Núm. 3, pp. 239-245

2016

  1. Assessment of effectiveness and security in high pressure postdilatation of bioresorbable vascular scaffolds during percutaneous coronary intervention. Study in a contemporary, non-selected cohort of Spanish patients

    International Journal of Cardiology, Vol. 219, pp. 264-270

  2. Dominancia coronaria y pronóstico a largo plazo de los pacientes con infarto de miocardio con elevación del segmento ST tratado con angioplastia primaria

    Revista Espanola de Cardiologia, Vol. 69, Núm. 1, pp. 19-27

  3. Mehran contrast nephropathy risk score: Is it still useful 10 years later?

    Journal of Cardiology, Vol. 67, Núm. 3, pp. 262-267

2015

  1. Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome

    Biomarkers in Medicine, Vol. 9, Núm. 3, pp. 209-216

  2. Relation of contrast induced nephropathy to new onset atrial fibrillation in acute coronary syndrome

    American Journal of Cardiology, Vol. 115, Núm. 5, pp. 587-591

2014

  1. Contrast-induced nephropathy and bleeding: A bidirectional link with prognostic value in acute coronary syndrome

    International Journal of Cardiology, Vol. 176, Núm. 1, pp. 235-236

2013

  1. Dosing of iodinated contrast volume: A new simple algorithm to stratify the risk of contrast-induced nephropathy in patients with acute coronary syndrome: A New Simple Algorithm to Stratify the Risk of Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome

    Catheterization and Cardiovascular Interventions, Vol. 82, Núm. 6, pp. 888-897

  2. Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome

    PLoS ONE, Vol. 8, Núm. 9

  3. High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction

    Revista Portuguesa de Cardiologia, Vol. 32, Núm. 2, pp. 117-122

  4. Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: Evidence in patients with acute myocardial infarction

    European Journal of Pharmaceutical Sciences, Vol. 49, Núm. 4, pp. 512-518

2012

  1. Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report

    Cardiovascular Diabetology, Vol. 11

2011

  1. Acute hyperglycemia: Is really a new risk marker for contrast-induced nephropathy in patients with acute myocardial infarction without diabetes and normal renal function?

    American Heart Journal